Phase 3 trial to test extended deucrictibant as treatment for HAE

Pharvaris said it plans to initiate a Phase 3 clinical trial by the end of the year to test an oral, extended-release tablet formulation of deucrictibant as a preventive, or prophylactic, treatment for hereditary angioedema (HAE). Called CHAPTER-3, the trial will assess the treatment’s safety and efficacy…

Preparations underway for Phase 3 trial of deucrictibant

Regulatory authorities in Japan, the U.S., and the European Union have aligned on plans for a Phase 3 clinical trial to test the oral medication deucrictibant as a prophylactic (preventive) treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE). With alignment from the U.S.

Pharvaris gearing up to launch Phase 3 trial of PHVS416 in 2024

Pharvaris is now gearing up startup activities with clinical site investigators and staff to launch a Phase 3 trial next year of PHVS416 — an immediate-release capsule formulation of deucrictibant — as an on-demand treatment for hereditary angioedema (HAE). The Switzerland-based clinical-stage company recently met with the U.S. Food…

KONFIDENT trial of sebetralstat for HAE fully enrolled

The Phase 3 clinical trial of oral sebetralstat as an on-demand treatment for swelling attacks in people with hereditary angioedema (HAE) has reached its target enrollment of 114 patients. Findings from the global KONFIDENT study (NCT05259917) are expected by year’s end, according to the therapy’s developer,…